Informing interventions to improve uptake of adjuvant endocrine therapy in women with breast cancer: a theoretical-based examination of modifiable influences on non-adherence
暂无分享,去创建一个
C. Kelly | S. Dombrowski | E. Watson | M. Wells | C. Cahir | K. Bennett | L. Sharp
[1] R. Olofsson Bagge,et al. Women’s coping strategies during the first three months of adjuvant endocrine therapy for breast cancer , 2019, Nursing open.
[2] Lyndsay D. Hughes,et al. Development of a self-management intervention to improve tamoxifen adherence in breast cancer survivors using an Intervention Mapping framework , 2019, Supportive Care in Cancer.
[3] Lyndsay D. Hughes,et al. Nonadherence to tamoxifen in breast cancer survivors: A 12 month longitudinal analysis. , 2019, Health psychology : official journal of the Division of Health Psychology, American Psychological Association.
[4] J. Borrás,et al. Influence of adherence to adjuvant endocrine therapy on disease-free and overall survival: a population-based study in Catalonia, Spain , 2019, Breast Cancer Research and Treatment.
[5] R. Horne,et al. Supporting Adherence to Medicines for Long-Term Conditions: A Perceptions and Practicalities Approach Based on an Extended Common-Sense Model , 2019, European Psychologist.
[6] A. Salner,et al. Interventions to promote adherence to endocrine therapy among breast cancer survivors: A meta‐analysis , 2018, Psycho-oncology.
[7] A. Stanton,et al. Correspondence Between Objective and Self-reported Endocrine Therapy Adherence Among Women With Breast Cancer. , 2019, Annals of behavioral medicine : a publication of the Society of Behavioral Medicine.
[8] Tisha M Felder,et al. A systematic review of interventions to improve adherence to endocrine therapy , 2018, Breast Cancer Research and Treatment.
[9] C. Gotay,et al. Understanding adjuvant endocrine therapy persistence in breast Cancer survivors , 2018, BMC cancer.
[10] V. Harvey,et al. Predicting nonadherence to adjuvant endocrine therapy in women with early stage breast cancer , 2018, Psycho-oncology.
[11] Melissa Matz,et al. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries , 2018, The Lancet.
[12] C. Gotay,et al. Patient-reported factors associated with adherence to adjuvant endocrine therapy after breast cancer: an integrative review , 2018, Breast Cancer Research and Treatment.
[13] J. Wisnivesky,et al. Patient-provider communication and hormonal therapy side effects in breast cancer survivors , 2017, Women & health.
[14] N. Barnett,et al. Using Theory to Explore the Determinants of Medication Adherence; Moving Away from a One-Size-Fits-All Approach , 2017, Pharmacy.
[15] M. Browall,et al. Assessing patient outcomes and cost‐effectiveness of nurse‐led follow‐up for women with breast cancer – have relevant and sensitive evaluation measures been used? , 2017, Journal of clinical nursing.
[16] J. Cuzick,et al. Participant-Reported Symptoms and Their Effect on Long-Term Adherence in the International Breast Cancer Intervention Study I (IBIS I) , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] K. Bennett,et al. Developing and validating a theoretical measure of modifiable influences on hormonal therapy medication taking behaviour in women with breast cancer , 2017, Psychology & health.
[18] K. Bennett,et al. Can demographic, clinical and treatment-related factors available at hormonal therapy initiation predict non-persistence in women with stage I–III breast cancer? , 2017, Cancer Causes & Control.
[19] Jinbo Chen,et al. Perceived barriers to treatment predict adherence to aromatase inhibitors among breast cancer survivors , 2017, Cancer.
[20] E. Smets,et al. Use of implicit persuasion in decision making about adjuvant cancer treatment: A potential barrier to shared decision making. , 2016, European journal of cancer.
[21] V. Sheppard,et al. Behavioral Interventions to Enhance Adherence to Hormone Therapy in Breast Cancer Survivors: A Systematic Literature Review. , 2016, Clinical breast cancer.
[22] Aaron N. Winn,et al. The association between trajectories of endocrine therapy adherence and mortality among women with breast cancer , 2016, Pharmacoepidemiology and drug safety.
[23] Jason D. Wright,et al. Psychosocial factors related to non-persistence with adjuvant endocrine therapy among women with breast cancer: the Breast Cancer Quality of Care Study (BQUAL) , 2016, Breast Cancer Research and Treatment.
[24] R. Horne,et al. Applying a perceptions and practicalities approach to understanding nonadherence to antiepileptic drugs , 2015, Epilepsia.
[25] K. Bennett,et al. Women’s experiences of hormonal therapy for breast cancer: exploring influences on medication-taking behaviour , 2015, Supportive Care in Cancer.
[26] K. Bennett,et al. A nested case–control study of adjuvant hormonal therapy persistence and compliance, and early breast cancer recurrence in women with stage I–III breast cancer , 2013, British Journal of Cancer.
[27] F. Song,et al. A meta-analysis of cognitive-based behaviour change techniques as interventions to improve medication adherence , 2013, BMJ Open.
[28] C. Abraham,et al. The Behavior Change Technique Taxonomy (v1) of 93 Hierarchically Clustered Techniques: Building an International Consensus for the Reporting of Behavior Change Interventions , 2013, Annals of behavioral medicine : a publication of the Society of Behavioral Medicine.
[29] Sally W. Vernon,et al. Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review , 2012, Breast Cancer Research and Treatment.
[30] Jeffrey K Aronson,et al. A new taxonomy for describing and defining adherence to medications. , 2012, British journal of clinical pharmacology.
[31] S. Michie,et al. Validation of the theoretical domains framework for use in behaviour change and implementation research , 2012, Implementation Science.
[32] Early Breast Cancer Trialists' Collaborative Group. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials , 2011, The Lancet.
[33] M. Tsolaki,et al. A Multiple Indicators Multiple Causes (MIMIC) model of Behavioural and Psychological Symptoms in Dementia (BPSD) , 2011, Neurobiology of Aging.
[34] S. Iacobelli,et al. Discussion about switch strategy in the adjuvant hormonal therapy of breast cancer: psychological aspects of physician-patient communication. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[35] Mahendra Patel,et al. Medicines adherence: Involving patients in decisions about prescribed medicines and supporting adherence , 2009 .
[36] L. Fallowfield,et al. Recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapy , 2007, Breast Cancer Research and Treatment.
[37] Ann E. Kurth,et al. Self-Report Measures of Antiretroviral Therapy Adherence: A Review with Recommendations for HIV Research and Clinical Management , 2006, AIDS and Behavior.
[38] S. Erickson,et al. The Concordance of Self-Report With Other Measures of Medication Adherence: A Summary of the Literature , 2004, Medical care.
[39] J. Weinman,et al. Patients' beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. , 1999, Journal of psychosomatic research.
[40] C. Carver. You want to measure coping but your protocol’ too long: Consider the brief cope , 1997, International journal of behavioral medicine.
[41] D. Watson,et al. Constructing validity: Basic issues in objective scale development , 1995 .
[42] C. Fornell,et al. Evaluating Structural Equation Models with Unobservable Variables and Measurement Error , 1981 .
[43] C. Fornell,et al. Evaluating structural equation models with unobservable variables and measurement error. , 1981 .
[44] A. Cunliffe. A SUMMARY OF THE LITERATURE , 1924 .